Reduction in pulmonary fibrosis in vivo by halofuginone.
Pulmonary fibrosis is a disorder causing a high mortality rate for which therapeutic options are limited. Therefore, the effect of halofuginone, a novel inhibitor of collagen type I synthesis, on bleomycin-induced pulmonary fibrosis was studied in rats. Pulmonary fibrosis was induced by intraperitoneal injections of bleomycin for seven consecutive days, and halofuginone was administered intraperitoneally every second day during the entire experimental period of 42 d. Collagen determination in the lungs and the examination of histologic sections showed that halofuginone significantly reduced fibrosis relative to the untreated control rats. We conclude that halofuginone is a potent in vivo inhibitor of bleomycin-induced pulmonary fibrosis, and that it may potentially be used as a novel therapeutic agent for the treatment of this dysfunction.
Nagler
A
A
Department of Bone Marrow Transplantation, Hadassah University Hospital, Israel.
Firman
N
N
Feferman
R
R
Cotev
S
S
Pines
M
M
Shoshan
S
S
D000818:Animals; D001761:Bleomycin; D003094:Collagen / Q000037:antagonists & inhibitors; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008297:Male; D010880:Piperidines; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D052999:Quinazolinones; D051381:Rats; D011919:Rats, Inbred Strains
D010880:Piperidines; D011799:Quinazolines; D052999:Quinazolinones; D001761:Bleomycin; D003094:Collagen; C010176:halofuginone